Edgewise Therapeutics Inc (EWTX) Stock Price, Quote & News

Company Profile

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other sever...

Industry: Biotechnology

Sector: Healthcare

Phone: 720 262 7002

Website: edgewisetx.com

Address:

1715 38th Street, Boulder, United States

Quantumup Mar. 13 at 12:48 PM

Cantor reiterated $CAPR Overweight; $62 after CAPR reported 4Q25 earnings. $EWTX $DYN SLDB PTCT SRPT Cantor said— Of course, the focus of the call was on CAPR's recent announcements of the 8/22/26 PDUFA for deramiocel (cardiosphere-derived cell therapy in DMD) + new HOPE-3 data that were presented at MDA. Capricor remains focused on the label potentially including cardiomyopathy (as well as ambulatory DMD), noting the distinction can go a long way with physicians. This will be discussed with the FDA once labeling discussions start. The FDA hasn't discussed differences between Cohort A (Los Angeles) and Cohort B (San Diego) for a while, but highlighted that Cohort B, which will be the commercial site, was statistically significant alone in itself. The San Diego facility could support ~250 patients per year (and potential stockpiling), and the company is expanding, which may ultimately lead to supporting ~2,500 patients per year.

0 · Reply

Trainguy1 Mar. 13 at 12:45 PM

$EWTX @S_Franconi The latest update from Edgewise Therapeutics, Inc. confirms completion of a Phase 1 study called “A Phase 1, 2-Part, Open-Label Study to Evaluate the Pharmacokinetics of a Single Oral Dose of EDG-7500 in Participants With Impaired and Normal Renal Function.” The study aims to see how the drug moves through the body in people with kidney problems versus healthy volunteers, and to check basic safety, which is key for later stage trials and dosing decisions.

1 · Reply

Trainguy1 Mar. 11 at 3:36 PM

$EWTX @S_Franconi We know "tutes" have confidence in EWTX's due to the very high rate of institutional ownership. Check out the following stats from NASDAQ (https://www.nasdaq.com/market-activity/stocks/ewtx/institutional-holdings)

0 · Reply

Trainguy1 Mar. 11 at 2:48 PM

$EWTX @S_Franconi So far today Wainwright and Truist have reiterated thier 52-week forecasts for EWTX. Expect more to come.

1 · Reply

S_Franconi Mar. 11 at 11:28 AM

$EWTX @Trainguy1 @Catlover37 600 watchers. 3/11/26

0 · Reply

Trainguy1 Mar. 11 at 1:30 AM

$EWTX I like the Wall St. analysts shown below who cover EWTX, especially Yasmeen Rahimi. Coincidentally, Yasmeen forecasted the highest 52 week target price on the board. Let’s see if Leerink will update the target price even higher after he meets with the Edgewise team tomorrow.

1 · Reply

Trainguy1 Mar. 10 at 10:53 PM

$CAPR $EWTX @S_Franconi

1 · Reply

Quantumup Mar. 10 at 2:43 PM

Leerink reiterated $CYTK Outperform; PT $84 $EWTX $BMY Here's what Leerink said in its note: https://x.com/Quantumup1/status/2031379784224133249?s=20

0 · Reply

Quantumup Mar. 10 at 2:29 PM

H.C. Wainwright reiterated $CAPR Buy/$60 $EWTX $PTCT SLDB $DYN $SRPT Here's what H.C. Wainwright said in its note to investors: https://x.com/Quantumup1/status/2031375649382838301?s=20

0 · Reply

Quantumup Mar. 10 at 12:58 PM

Truist reitd $EWTX Buy46 $CAPR Truist said—This morning Edgewise reported an update from the ongoing MESA Open-Label Extension trial that continues to show stabilization of function (measured by NSAA) in participants on sevasemten versus the predicted functional decline observed in BMD natural history studies. Today's update from MESA show stabilization from ARCH-rollover patients out to 42 months vs. 36 months prior readout, and in CANYON-rollover patients up to 24 months from 18 months reported previously. We believe the data continue to support sevasemten's efficacy benefit in BMD, for which there are no approved therapies. Our recent investor conversations show that the focus for Edgewise continues to be on their HCM program, with less attention to the progress with sevasemten. Accordingly, we think the BMD program may be under the radar for many investors, and we believe there could be meaningful share upside with positive GRAND CANYON data in 4Q2026 that could be registration-enabling.

0 · Reply

Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up

Mar 4, 2026, 8:00 AM EST - 12 days ago

Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026

Mar 3, 2026, 8:00 AM EST - 13 days ago

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference

Mar 2, 2026, 9:30 AM EST - 13 days ago

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Feb 26, 2026, 8:00 AM EST - 18 days ago

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs

Feb 5, 2026, 8:00 AM EST - 5 weeks ago

Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026

Jan 13, 2026, 2:05 PM EST - 2 months ago

Edgewise Therapeutics, Inc. (EWTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 13, 2026, 8:00 AM EST - 2 months ago

Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026

Jan 6, 2026, 8:00 AM EST - 2 months ago

Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

Dec 29, 2025, 2:55 PM EST - 2 months ago

Edgewise: Maintaining Buy On Part D EDG-7500 Data And Next Q2 2026 Catalyst

Dec 26, 2025, 8:12 AM EST - 2 months ago

Why Did Edgewise Therapeutics Jump 25%+ On Wednesday?

Dec 24, 2025, 8:00 AM EST - 2 months ago

Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy

Dec 4, 2025, 3:53 AM EST - 3 months ago

Edgewise Therapeutics, Inc. (EWTX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Nov 20, 2025, 8:00 AM EST - 4 months ago

Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors

Nov 10, 2025, 8:00 AM EST - 4 months ago

Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers

Nov 7, 2025, 8:00 AM EST - 4 months ago

Edgewise Therapeutics to Participate in Upcoming Investor Conferences

Nov 6, 2025, 8:00 AM EST - 4 months ago

Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Oct 2, 2025, 8:00 AM EDT - 5 months ago

Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society

Aug 14, 2025, 3:53 PM EDT - 7 months ago

Edgewise Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Aug 7, 2025, 8:00 AM EDT - 7 months ago

Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jul 19, 2025, 6:58 PM EDT - 8 months ago

EWTX Investors Have Opportunity to Join Edgewise Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Jun 26, 2025, 6:00 AM EDT - 9 months ago

Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies

Jun 3, 2025, 8:00 AM EDT - 10 months ago

Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference

May 14, 2025, 8:00 AM EDT - 10 months ago

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025

May 8, 2025, 8:00 AM EDT - 11 months ago

Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Apr 10, 2025, 6:56 AM EDT - 1 year ago

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2

CAMP

Apr 2, 2025, 4:54 PM EDT - 1 year ago

Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On

Apr 2, 2025, 12:27 PM EDT - 1 year ago

Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study

Apr 2, 2025, 6:22 AM EDT - 1 year ago

Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock

Apr 2, 2025, 6:00 AM EDT - 1 year ago

Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM)

Mar 26, 2025, 4:45 PM EDT - 1 year ago

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference

Mar 10, 2025, 1:36 PM EDT - 1 year ago

Edgewise Therapeutics: More Expensive Now, But Much More Derisked

Mar 4, 2025, 8:00 AM EST - 1 year ago

Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025

Mar 3, 2025, 8:00 AM EST - 1 year ago

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Jan 22, 2025, 8:00 AM EST - 1 year ago

Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development

Jan 13, 2025, 8:00 AM EST - 1 year ago

Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025

Jan 7, 2025, 8:00 AM EST - 1 year ago

Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

Dec 31, 2024, 2:09 PM EST - 1 year ago

Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data

Dec 16, 2024, 11:56 AM EST - 1 year ago

Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease

Dec 16, 2024, 6:00 AM EST - 1 year ago

Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)

Dec 5, 2024, 2:32 PM EST - 1 year ago

Edgewise Provides Statement Regarding Company's Relationship with Dr. Han Phan at Rare Disease Research

Nov 26, 2024, 6:00 AM EST - 1 year ago

Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Oct 1, 2024, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society

Sep 30, 2024, 12:12 PM EDT - 1 year ago

Analysts Think There's Still Time To Get In On Edgewise

Sep 25, 2024, 11:50 AM EDT - 1 year ago

Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge

Quantumup Mar. 13 at 12:48 PM

0 · Reply

Trainguy1 Mar. 13 at 12:45 PM

1 · Reply

Trainguy1 Mar. 11 at 3:36 PM

0 · Reply

Trainguy1 Mar. 11 at 2:48 PM

$EWTX @S_Franconi So far today Wainwright and Truist have reiterated thier 52-week forecasts for EWTX. Expect more to come.

1 · Reply

S_Franconi Mar. 11 at 11:28 AM

$EWTX @Trainguy1 @Catlover37 600 watchers. 3/11/26

0 · Reply

Trainguy1 Mar. 11 at 1:30 AM

1 · Reply

Trainguy1 Mar. 10 at 10:53 PM

$CAPR $EWTX @S_Franconi

1 · Reply

Quantumup Mar. 10 at 2:43 PM

Leerink reiterated $CYTK Outperform; PT $84 $EWTX $BMY Here's what Leerink said in its note: https://x.com/Quantumup1/status/2031379784224133249?s=20

0 · Reply

Quantumup Mar. 10 at 2:29 PM

H.C. Wainwright reiterated $CAPR Buy/$60 $EWTX $PTCT SLDB $DYN $SRPT Here's what H.C. Wainwright said in its note to investors: https://x.com/Quantumup1/status/2031375649382838301?s=20

0 · Reply

Quantumup Mar. 10 at 12:58 PM

0 · Reply

S_Franconi Mar. 10 at 11:40 AM

$DYN $EWTX Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up https://investors.edgewisetx.com/news/news-details/2026/Edgewise-Announces-Positive-Long-Term-Sevasemten-Data-Demonstrating-Sustained-Functional-Stabilization-in-Becker-Muscular-Dystrophy-Through-3-5-Years-of-Follow-Up/default.aspx

0 · Reply

S_Franconi Mar. 10 at 11:38 AM

$EWTX Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up https://investors.edgewisetx.com/news/news-details/2026/Edgewise-Announces-Positive-Long-Term-Sevasemten-Data-Demonstrating-Sustained-Functional-Stabilization-in-Becker-Muscular-Dystrophy-Through-3-5-Years-of-Follow-Up/default.aspx

1 · Reply

Quantumup Mar. 9 at 2:45 PM

Jefferies reiterated $DYN Buy/$50, and said that it Remains 70-80%+ Confident in an AA Approval by 1Q27. $PEPG $RNA ARWR SNY $CAPR $EWTX PTCT SRPT Here's what Jefferies had to say in its note: At MDA (Mar 8-11): (1) In DM1 ($3B+ oppty), z-basivarsen (ASO) starts a confirmatory Phase III trial designed to convert an AA accelerated approval (based on pivotal Phase II results in Q1:27) into a full approval. (2) In DMD Exon 51 ($500M+ oppty), z-rostudirsen (PMO) shares new 24-month cardiopulmonary function data from the Phase I/II OLE extension. We remain 70-80%+ confident in an AA approval by Q1:27, due to recent best-in-class pivotal Phase II data.

0 · Reply

S_Franconi Mar. 3 at 1:50 PM

$EWTX Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference https://investors.edgewisetx.com/news/news-details/2026/Edgewise-Therapeutics-to-Present-on-Sevasemten-for-the-Treatment-of-Becker-Muscular-Dystrophy-at-the-2026-MDA-Clinical-and-Scientific-Conference/default.aspx

0 · Reply

S_Franconi Mar. 2 at 9:35 PM

$EWTX

0 · Reply

erevnon Feb. 27 at 2:27 PM

Evercore ISI Group maintains Edgewise Therapeutics $EWTX at Outperform and raises the price target from $30 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Quantumup Feb. 26 at 9:27 PM

Evercore ISI⬆️ $EWTX to $45 from $30 and reiterated at an Outperform rating $CYTK $BMY $CAPR Raymond James reit'd a Strong Buy rating/ a $46 PT on Edgewise Therapeutics Evercore ISI said: EWTX's quarterly update is largely business-as-usual, with the story still driven near-term by EDG-7500's 12-wk HCM data in 1H26e. Following the encouraging December update that reduced AF concern, attention is centered on a more fulsome efficacy update that can further derisk the program and inform the Ph3 path. Overall, we see the prior HCM and BMD datasets as having meaningfully de-risked the clinical setup for 2026. Raymond James said: This morning, EWTX announced 4Q25 financial results and provided a corporate update, with key clinical timelines on track. Following an encouraging interim safety update from CIRRUS HCM Part D in December, we continue to see a highly attractive long-term risk/reward skew for EWTX with Part D efficacy updates around the corner in 1H26. We reiterate our Strong Buy rating.

1 · Reply

S_Franconi Feb. 26 at 1:12 PM

$EWTX Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs https://investors.edgewisetx.com/news/news-details/2026/Edgewise-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-with-Strong-Progress-Across-Muscular-Dystrophy-and-Cardiovascular-Programs/default.aspx

0 · Reply

StockConsultant Feb. 25 at 2:17 PM

$EWTX Edgewise Therapeutics stock, nice trend, watch for a continuation breakout at https://stockconsultant.com/?EWTX

0 · Reply

Quantumup Feb. 25 at 2:09 PM

Needham⬆️the PT on $CYTK to $85 and reiterated at a Buy rating. $BMY $EWTX Needham said in its note: There was little in terms of a Myqorzo launch update in CYTK's 4Q25 update given the product only became commercially available in late-Jan. It will take 2-3 quarters to see how the launch is tracking and compares vs. Camzyos which generated sales of~$53MM in its first 4 qrtrs of launch. The upcoming 2Q26 readout of ACACIA-HCM in nHCM represents the key catalyst for CYTK, given its potential to not only meaningfully expand (potentially double) Myqorzo's market potential into nHCM but also significantly differentiate vs. Camzyos. We expect results in early-2Q26, with success likely achieved by meeting one or both of the dual primary endpoints (KCCQ or pVO2). We maintain our Buy rating and increase our $ PT to $85 (from $84) to reflect minor model adjustments. We note our model and valuation does not currently include Myqorzo sales in nHCM.

0 · Reply

Quantumup Feb. 25 at 12:04 PM

Citizens⬆️the PT on Top Pick $CYTK to $96 and reiterated at Market Outperform. $EWTX $BMY Here's what Citizens said in its note to investors: Cytokinetics remains our top pick ahead of ACACIA-HCM results next quarter; we reiterate our Market Outperform rating and increase our risk-adjusted, DCF-derived price target to $96 from $88. Yesterday afternoon, Cytokinetics reported 4Q25 financial results and business updates, providing insights into the initial weeks of the MYQORZO launch in obstructive hypertrophic cardiomyopathy (oHCM). HCPs are becoming certified for the REMS program (both current CMI and new-to-class prescribers), and prescriptions are being written and dispensed. As expected, many of the questions on the call focused on the upcoming Phase 3 non-obstructive HCM readout, and we continue to view the stock as a top pick ahead of these results.

0 · Reply

StocktwitsNews Feb. 18 at 4:52 AM

MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites $MLTX $MTSR $PRAX $BBIO $EWTX https://stocktwits.com/news/equity/markets/moon-lake-stock-soars-as-biotech-fund-reloads-takeover-chatter-ignites/cZR0WqyR4Hi

0 · Reply

Market Cap	3.17B
Revenue (ttm)	0.00
Net Income (ttm)	-167.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	702,200
Avg Vol	1,004,682
Day's Range	N/A - N/A
Shares Out	107.27M
Stochastic %K	61%
Beta	0.26
Analysts	Strong Sell
Price Target	$40.17